Meeting
2013 Genitourinary Cancers Symposium
Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).
Authors
Matthew Raymond Smith
Massachusetts General Hospital Cancer Center, Boston, MA
Matthew Raymond Smith , Susan Halabi , Charles J. Ryan , Walter Michael Stadler , Arif Hussain , Nicholas J. Vogelzang , Ralph J. Hauke , Ben L. Sanford , Eric Jay Small
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00079001
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 27)
DOI
10.1200/jco.2013.31.6_suppl.27
Abstract #
27
Poster Bd #
B18
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
First Author: Michael E. Rader
Poster
2012 Genitourinary Cancers Symposium
Skeletal events unrelated to bone metastasis in men with castration-refractory prostate cancer.
First Author: Kazumi Kamoi
Poster
2011 ASCO Annual Meeting
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain.
First Author: N. D. Shore
Poster
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
First Author: Aaron Philip Mitchell